FDA allows Aerie to change primary endpoint range for Rocket 2 trial of Rhopressa

The FDA has allowed Aerie Pharmaceuticals to change the primary endpoint range of Rocket 2, a second phase 3 registration trial of the glaucoma eye drop Rhopressa, the company announced in a press release.Aerie is changing the primary endpoint range to include patients with a baseline IOP ranging from above 20 mm Hg to under 25 mm Hg. The previous endpoint range of above 20 mm Hg to under 27 mm Hg will be a secondary endpoint range in Rocket 2, the release said.